SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Mannching Sherry Ku, Recent trends in specialty pharma business model, Journal of Food and Drug Analysis, 2015, 23, 4, 595

    CrossRef

  2. 2
    Andrew E. Podgorny, Supporting the Rationale Behind the Hatch-Waxman Act and Patent Law: How Reverse Payment Settlements Under FTC v. Actavis, Inc. Can Be Procompetitive, Indiana Health Law Review, 2015, 12, 1, 423

    CrossRef

  3. 3
    Bhaven N. Sampat, Kenneth C. Shadlen, TRIPS Implementation and Secondary Pharmaceutical Patenting in Brazil and India, Studies in Comparative International Development, 2015, 50, 2, 228

    CrossRef

  4. 4
    Kate S Gaudry, Daniel E Cummings, Patent office backlog adds billions to national drug expenditure, Nature Biotechnology, 2014, 32, 5, 436

    CrossRef

  5. 5
    A. K. Rai, G. Rice, Use Patents Can Be Useful: The Case of Rescued Drugs, Science Translational Medicine, 2014, 6, 248, 248fs30

    CrossRef

  6. 6
    C. S. Hemphill, B. Sampat, Drug Patents at the Supreme Court, Science, 2013, 339, 6126, 1386

    CrossRef

  7. 7
    Amy Kapczynski, Engineered in India — Patent Law 2.0, New England Journal of Medicine, 2013, 369, 6, 497

    CrossRef

  8. 8
    B. N. Sampat, K. C. Shadlen, T. M. Amin, Challenges to India's Pharmaceutical Patent Laws, Science, 2012, 337, 6093, 414

    CrossRef

  9. 9
    C. Scott Hemphill, Bhaven N. Sampat, Evergreening, patent challenges, and effective market life in pharmaceuticals, Journal of Health Economics, 2012, 31, 2, 327

    CrossRef